2026-04-26T23:36:59Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/204222024-11-29T01:01:57Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967

00925njm 22002777a 4500 dc Almeida, Antonio M author Prebet, Thomas author Itzykson, Raphael author Ramos, Fernando author Al-Ali, Haifa author Shammo, Jamile author Pinto, Ricardo author Maurillo, Luca author Wetzel, Jaime author Musto, Pellegrino author Van De Loosdrecht, Arjan A author Costa, Maria Joao author Esteves, Susana author Burgstaller, Sonja author Stauder, Reinhard author Autzinger, Eva M author Lang, Alois author Krippl, Peter author Geissler, Dietmar author Falantes, Jose F author Pedro, Carmen author Bargay Lleonart, Joan author Deben, Guillermo author Garrido, Ana author Bonanad, Santiago author Diez-Campelo, Maria author Thepot, Sylvain author Ades, Lionel author Sperr, Wolfgang R author Valent, Peter author Fenaux, Pierre author Sekeres, Mikkael A author Greil, Richard author Pleyer, Lisa author 2017-04 Acute erythroleukemia (AEL) is a rare disease typically associated with a poor prognosis. The median survival ranges between 3-9 months from initial diagnosis. Hypomethylating agents (HMAs) have been shown to prolong survival in patients with myelodysplastic syndromes (MDS) and AML, but there is limited data of their efficacy in AEL. We collected data from 210 AEL patients treated at 28 international sites. Overall survival (OS) and PFS were estimated using the Kaplan-Meier method and the log-rank test was used for subgroup comparisons. Survival between treatment groups was compared using the Cox proportional hazards regression model. Eighty-eight patients were treated with HMAs, 44 front line, and 122 with intensive chemotherapy (ICT). ICT led to a higher overall response rate (complete or partial) compared to first-line HMA (72% vs. 46.2%, respectively; p <= 0.001), but similar progression-free survival (8.0 vs. 9.4 months; p = 0.342). Overall survival was similar for ICT vs. HMAs (10.5 vs. 13.7 months; p = 0.564), but patients with high-risk cytogenetics treated with HMA first-line lived longer (7.5 for ICT vs. 13.3 months; p = 0.039). Our results support the therapeutic value of HMA in AEL. Almeida AM, Prebet T, Itzykson R, Ramos F, Al-Ali H, Shammo J, et al. Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study. Int J Mol Sci. 2017 Apr;18(4):837. http://hdl.handle.net/20.500.13003/9895 http://hdl.handle.net/20.500.12105/20422 28420120 10.3390/ijms18040837 1422-0067 International Journal of Molecular Sciences 2-s2.0-85018470782 402639400161 L615479846 Acute erythroleukemia Azacitidine Decitabine Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study